-
Something wrong with this record ?
Newborn Hearing Screening - An Implementation Analysis
T. Kostlivý, P. Škopek, P. Klail, H. Laierová, A. Skálová, B. Gál, R. Kučera, V. Šimánek, D. Slouka
Language English Country Greece
Document type Journal Article
NLK
PubMed Central
from 2017
Europe PubMed Central
from 2017
Open Access Digital Library
from 2004-01-01
PubMed
38936904
DOI
10.21873/invivo.13650
Knihovny.cz E-resources
- MeSH
- Humans MeSH
- Hearing Loss * diagnosis epidemiology MeSH
- Infant, Newborn MeSH
- Neonatal Screening * methods MeSH
- Hearing Tests * methods MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Infant, Newborn MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND/AIM: Hearing impairment affects a small but significant percentage of newborns (0.1-0.4%). Newborn hearing screening (NHS) is recommended for early detection and treatment. The implementation of NHS can vary among countries. In this study, we present the methodology, organization, and technical requirements of NHS. This study analyzed results from a tertiary hospital, identified issues, and proposed solutions. PATIENTS AND METHODS: In the studied region, there are five maternity hospitals and a perinatal intensive care center and in 2020, there were 5,864 live births. Screening is performed at three levels. The first screening is conducted on the 2nd-3rd day of a newborn's life in a maternity hospital, the first rescreening on the 3rd-6th week at a relevant ENT department, and the second rescreening on the 3rd-6th month of life at the regional screening center where the central database is also held. RESULTS: In the studied region, 5,793 out of 5,864 (98.79%) newborns received NHS in 2020. Of these, 120 (2.07%) were tested positive on their first screening. Ninety-four patients (78.3%) of those attended the ENT department for a first rescreening. Thirty-four patients (0.59% of total) were tested positive again and referred to the regional screening center. Out of the 27 patients who attended the second rescreening, four (0.07% of the total) were ultimately diagnosed with hearing impairment. CONCLUSION: Our study found that newborn hearing screening (NHS) in our region achieved a high compliance rate of 98.8% for initial screenings in 2020. However, challenges remain in the rescreening process due to data management issues, inter-regional cooperation, and public awareness. The recent implementation of mandatory screenings, updated guidelines, and a centralized database is expected to enhance the effectiveness of NHS. Further research is needed to evaluate these improvements.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013336
- 003
- CZ-PrNML
- 005
- 20250129143914.0
- 007
- ta
- 008
- 240725s2024 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/invivo.13650 $2 doi
- 035 __
- $a (PubMed)38936904
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Kostlivý, Tomáš $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 245 10
- $a Newborn Hearing Screening - An Implementation Analysis / $c T. Kostlivý, P. Škopek, P. Klail, H. Laierová, A. Skálová, B. Gál, R. Kučera, V. Šimánek, D. Slouka
- 520 9_
- $a BACKGROUND/AIM: Hearing impairment affects a small but significant percentage of newborns (0.1-0.4%). Newborn hearing screening (NHS) is recommended for early detection and treatment. The implementation of NHS can vary among countries. In this study, we present the methodology, organization, and technical requirements of NHS. This study analyzed results from a tertiary hospital, identified issues, and proposed solutions. PATIENTS AND METHODS: In the studied region, there are five maternity hospitals and a perinatal intensive care center and in 2020, there were 5,864 live births. Screening is performed at three levels. The first screening is conducted on the 2nd-3rd day of a newborn's life in a maternity hospital, the first rescreening on the 3rd-6th week at a relevant ENT department, and the second rescreening on the 3rd-6th month of life at the regional screening center where the central database is also held. RESULTS: In the studied region, 5,793 out of 5,864 (98.79%) newborns received NHS in 2020. Of these, 120 (2.07%) were tested positive on their first screening. Ninety-four patients (78.3%) of those attended the ENT department for a first rescreening. Thirty-four patients (0.59% of total) were tested positive again and referred to the regional screening center. Out of the 27 patients who attended the second rescreening, four (0.07% of the total) were ultimately diagnosed with hearing impairment. CONCLUSION: Our study found that newborn hearing screening (NHS) in our region achieved a high compliance rate of 98.8% for initial screenings in 2020. However, challenges remain in the rescreening process due to data management issues, inter-regional cooperation, and public awareness. The recent implementation of mandatory screenings, updated guidelines, and a centralized database is expected to enhance the effectiveness of NHS. Further research is needed to evaluate these improvements.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a novorozenec $7 D007231
- 650 12
- $a novorozenecký screening $x metody $7 D015997
- 650 12
- $a sluchové testy $x metody $7 D006320
- 650 12
- $a nedoslýchavost $x diagnóza $x epidemiologie $7 D034381
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Škopek, Petr $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Klail, Pavel, $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $d 1995- $7 xx0328572
- 700 1_
- $a Laierová, Hana $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Skálová, Alena $u Department of Pathology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Gál, Břetislav $u Department of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Kučera, Radek $u Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Šimánek, Václav $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Slouka, David $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; slouka@fnplzen.cz
- 773 0_
- $w MED00175831 $t In Vivo $x 1791-7549 $g Roč. 38, č. 4 (2024), s. 1939-1946
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38936904 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20250129143909 $b ABA008
- 999 __
- $a ok $b bmc $g 2143258 $s 1225202
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 4 $d 1939-1946 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
- LZP __
- $a Pubmed-20240725